MGMT promoter methylation status prediction using MRI scans? An extensive experimental evaluation of deep learning models

• URL: http://arxiv.org/abs/2304.00774v1
• Date: Mon, 3 Apr 2023 07:55:42 GMT
• Title: MGMT promoter methylation status prediction using MRI scans? An extensive experimental evaluation of deep learning models
• Authors: Numan Saeed, Muhammad Ridzuan, Hussain Alasmawi, Ikboljon Sobirov, Mohammad Yaqub
• Abstract summary: We employ deep learning models to predict the methylation status of the MGMT promoter in glioblastoma tumors using MRI scans. Our results show no correlation between these models' performance to assure the accuracy and reliability of deep learning systems in cancer diagnosis.
• Score: 0.0
• License: http://creativecommons.org/licenses/by-nc-sa/4.0/
• Abstract: The number of studies on deep learning for medical diagnosis is expanding, and these systems are often claimed to outperform clinicians. However, only a few systems have shown medical efficacy. From this perspective, we examine a wide range of deep learning algorithms for the assessment of glioblastoma - a common brain tumor in older adults that is lethal. Surgery, chemotherapy, and radiation are the standard treatments for glioblastoma patients. The methylation status of the MGMT promoter, a specific genetic sequence found in the tumor, affects chemotherapy's effectiveness. MGMT promoter methylation improves chemotherapy response and survival in several cancers. MGMT promoter methylation is determined by a tumor tissue biopsy, which is then genetically tested. This lengthy and invasive procedure increases the risk of infection and other complications. Thus, researchers have used deep learning models to examine the tumor from brain MRI scans to determine the MGMT promoter's methylation state. We employ deep learning models and one of the largest public MRI datasets of 585 participants to predict the methylation status of the MGMT promoter in glioblastoma tumors using MRI scans. We test these models using Grad-CAM, occlusion sensitivity, feature visualizations, and training loss landscapes. Our results show no correlation between these two, indicating that external cohort data should be used to verify these models' performance to assure the accuracy and reliability of deep learning systems in cancer diagnosis.

Related papers

• Enhancing Trust in Clinically Significant Prostate Cancer Prediction with Multiple Magnetic Resonance Imaging Modalities [61.36288157482697]
  In the United States, prostate cancer is the second leading cause of deaths in males with a predicted 35,250 deaths in 2024. In this paper, we investigate combining multiple MRI modalities to train a deep learning model to enhance trust in the models for clinically significant prostate cancer prediction.
  arXiv  Detail & Related papers  (2024-11-07T12:48:27Z)
• Using Multiparametric MRI with Optimized Synthetic Correlated Diffusion Imaging to Enhance Breast Cancer Pathologic Complete Response Prediction [71.91773485443125]
  Neoadjuvant chemotherapy has recently gained popularity as a promising treatment strategy for breast cancer. The current process to recommend neoadjuvant chemotherapy relies on the subjective evaluation of medical experts. This research investigates the application of optimized CDI$s$ to enhance breast cancer pathologic complete response prediction.
  arXiv  Detail & Related papers  (2024-05-13T15:40:56Z)
• Treatment-aware Diffusion Probabilistic Model for Longitudinal MRI Generation and Diffuse Glioma Growth Prediction [0.5806504980491878]
  We present a novel end-to-end network capable of generating future tumor masks and realistic MRIs of how the tumor will look at any future time points. Our approach is based on cutting-edge diffusion probabilistic models and deep-segmentation neural networks.
  arXiv  Detail & Related papers  (2023-09-11T12:12:52Z)
• Prediction of brain tumor recurrence location based on multi-modal fusion and nonlinear correlation learning [55.789874096142285]
  We present a deep learning-based brain tumor recurrence location prediction network. We first train a multi-modal brain tumor segmentation network on the public dataset BraTS 2021. Then, the pre-trained encoder is transferred to our private dataset for extracting the rich semantic features. Two decoders are constructed to jointly segment the present brain tumor and predict its future tumor recurrence location.
  arXiv  Detail & Related papers  (2023-04-11T02:45:38Z)
• Artificial-intelligence-based molecular classification of diffuse gliomas using rapid, label-free optical imaging [59.79875531898648]
  DeepGlioma is an artificial-intelligence-based diagnostic screening system. DeepGlioma can predict the molecular alterations used by the World Health Organization to define the adult-type diffuse glioma taxonomy.
  arXiv  Detail & Related papers  (2023-03-23T18:50:18Z)
• Artificial Intelligence Solution for Effective Treatment Planning for Glioblastoma Patients [0.0]
  Glioblastomas are the most common malignant brain tumors in adults. Approximately 200000 people die each year from Glioblastoma in the world. Glioblastoma patients have a median survival of 12 months with optimal therapy and about 4 months without treatment.
  arXiv  Detail & Related papers  (2022-03-09T22:29:48Z)
• Is it Possible to Predict MGMT Promoter Methylation from Brain Tumor MRI Scans using Deep Learning Models? [0.0]
  Glioblastoma is a common brain malignancy that tends to occur in older adults and is almost always lethal. To identify the state of the MGMT promoter, the conventional approach is to perform a biopsy for genetic analysis. A couple of recent publications proposed a connection between the MGMT promoter state and the MRI scans of the tumor.
  arXiv  Detail & Related papers  (2022-01-16T16:44:21Z)
• Optimizing Prediction of MGMT Promoter Methylation from MRI Scans using Adversarial Learning [0.0]
  It is estimated that annually over 13,000 deaths occur in the US due to Glioblastoma Multiforme (GBM) It is important to identify the MGMT promoter status through non-invasive magnetic resonance imaging (MRI) based machine learning (ML) models. We developed four primary models - two radiomic models and two CNN models - each solving the binary classification task with progressive improvements.
  arXiv  Detail & Related papers  (2022-01-12T11:04:34Z)
• Novel Local Radiomic Bayesian Classifiers for Non-Invasive Prediction of MGMT Methylation Status in Glioblastoma [0.0]
  Expression of the O6-methylguanine-DNA-methyltransferase (MGMT) gene in glioblastoma tumor tissue is of clinical importance. Currently, MGMT methylation is determined through an invasive brain biopsy and subsequent genetic analysis of the extracted tumor tissue. We present novel Bayesian classifiers that make probabilistic predictions of MGMT methylation status based on radiomic features extracted from FLAIR-sequence magnetic resonance imagery (MRIs)
  arXiv  Detail & Related papers  (2021-11-30T04:53:23Z)
• Learned super resolution ultrasound for improved breast lesion characterization [52.77024349608834]
  Super resolution ultrasound localization microscopy enables imaging of the microvasculature at the capillary level. In this work we use a deep neural network architecture that makes effective use of signal structure to address these challenges. By leveraging our trained network, the microvasculature structure is recovered in a short time, without prior PSF knowledge, and without requiring separability of the UCAs.
  arXiv  Detail & Related papers  (2021-07-12T09:04:20Z)
• Spectral-Spatial Recurrent-Convolutional Networks for In-Vivo Hyperspectral Tumor Type Classification [49.32653090178743]
  We demonstrate the feasibility of in-vivo tumor type classification using hyperspectral imaging and deep learning. Our best model achieves an AUC of 76.3%, significantly outperforming previous conventional and deep learning methods.
  arXiv  Detail & Related papers  (2020-07-02T12:00:53Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.